Posted by Michael Wonder on 04 Aug 2025
Dyne Therapeutics announces FDA breakthrough therapy designation for DYNE-251 in Duchenne muscular dystrophy
4 August 2025 - Dyne Therapeutics today announced that the US FDA has granted breakthrough therapy designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy, amenable to exon 51 skipping.
The designation is based on data from the ongoing DELIVER clinical trial.
